|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.87 / 2.12|
MEI Pharma (MEIP) stock is surging in early-morning trading on Monday, after the oncology company announced positive results from its leukemia treatment's Phase II trial.
American Society of Hematology Annual Meeting Abstracts Now Available
Live Webcast from San Francisco on October 21st
Live Webcast from New York on August 11th
Live Webcast from New York on July 8th
Clinical Responses Continue to Improve; Median Overall Survival Not Yet Reached
Live Webcast from Las Vegas on May 13th
New Studies Identify Molecular Target, Mitochondria-Specific Effects of ME-344; Results from First-in-Human Clinical Study Published in Cancer
Shares of MEI Pharma (MEIP) were up in late morning trading Tuesday as investors swooped into the stock following its significant decline on Monday.
Shares of MEI Pharma (MEIP) plunged to a one-year low on Monday after the company announced its cancer drug Pracinostat failed to meet its main goal in a mid-stage trial.
Company Provides Update on Clinical Development Plans
Live Webcast from Boston on March 4th
Investors in MEI Pharma Inc saw new options become available this week, for the April 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the MEIP options chain for the new April 17th contracts and identified one put and one call contract of particular interest.
Keep these under-$10 biotech stocks on your breakout trading radar.
These setups often produce monster moves higher in very short time frames.
Chapter Establishes New Co-Presidency Leadership Structure and Forms Advisory Committee
Company Outlines Plans for Phase III Registration Study